A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

NCT04537923 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1428

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Tirzepatide
DRUG: Insulin Lispro (U100)

Sponsor

Eli Lilly and Company